GlassScriptPhysician profile
Robert Provenzano
NPI 1972505584
$45,008.17
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $24K · 2021: $10K · 2023: $71.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $71.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $71.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26,257.50 | 2019-2021 | |
| Rockwell Medical, INC. | $16,800.00 | 2020-2021 | |
| Boehringer Ingelheim International Gmbh | $1,303.98 | 2019 | |
| Astrazeneca Uk Limited | $432.91 | 2019 | |
| Baxter Healthcare | $142.15 | 2019 | |
| Outset Medical INC | $71.63 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Provenzano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.